# Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia

> **NCT00716274** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 110 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder
- Dyslexia

## Interventions

- **DRUG:** Atomoxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00716274
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2022-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00716274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00716274, "Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00716274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*